Liezl Gambe

Endeavour Group (ASX:EDV) reported modest sales growth but softer earnings in a trading update for the first half of the 2026 financial year ended Jan. 4.

Amphenol Corp. (NYSE:APH) completed its acquisition of CommScope’s Connectivity and Cable Solutions (CCS) business on Monday, a transformational $10.5 billion deal that cements its position as a dominant provider of the hardware underpinning the artificial intelligence revolution.

Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.

Shake Shack (NYSE:SHAK) signaled a period of aggressive expansion and improving profitability, issuing an upbeat 2026 outlook that highlights its evolution from a cult favorite to a dominant global restaurant platform.

OneSpaWorld Holdings Limited (NASDAQ:OSW) projected its annual revenue will surpass the $1 billion mark for the first time in 2026, as the company streamlines its global operations to capitalize on a record-breaking surge in cruise ship travel.

J.Jill (NYSE:JILL) raised its fourth-quarter and full-year financial guidance on Monday, citing a "stronger-than-anticipated" conclusion to the 2025 holiday season as the retailer prepares for key investor meetings at the ICR Conference.

Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration with GSK (NYSE:GSK) to evaluate the combination of ivonescimab, Summit’s novel investigational PD-1/VEGF bispecific antibody, with risvutatug rezetecan (GSK’227), GSK’s investigational B7-H3-targeting antibody-drug conjugate (ADC), in multiple solid tumor settings, including small cell lung cancer (SCLC).

West Pharmaceutical Services (NYSE:WST), a leading provider of injectable packaging and delivery systems, announced it has entered into a definitive agreement to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie (NYSE:ABBV) for $112.5 million in cash at closing, subject to customary working capital and other adjustments.

Amsterdam, Netherlands- and Boston-based argenx SE (NASDAQ:ARGX), a global immunology company, reported preliminary full-year 2025 global product net sales of $4.15 billion, reflecting strong commercial momentum for its flagship FcRn antagonist VYVGART (efgartigimod) and its subcutaneous formulation VYVGART Hytrulo.

Soaring energy prices are leaving millions of US families struggling to pay electricity and gas bills this winter.